Samtidig anvendelse resulterer i en 8 gange stigning i repaglinid- plasmakoncentrationen, sandsynligvis på grund af hæmningen af CYP2C8 enzymet, som dermed fører til hypoglykæmiske reaktioner.
Concomitant administration has resulted in 8-fold increase in repaglinide plasma concentration probably by inhibition of the CYP2C8 enzyme, resulting in hypoglycaemic reactions.